FDA approved Otarmeni 61 days after BLA filing, calling it the first gene-therapy product approved under the Commissioner's National Priority Voucher pilot and tied for the fastest BLA approval in modern FDA history. [1]

On Sunday, the paper argued that Otarmeni put the National Priority Voucher pilot on trial before the June hearing. Monday's version has a clearer test case: approval first, governance calendar next.

The FDA has scheduled a June 4 public meeting and a June 29 comment deadline on the pilot's criteria, sponsor responsibilities, review council, and procedures. [2][3] That means the program's legitimacy will not be judged only by speed. It will be judged by whether the public can see why this product belonged in the fast lane.

For patients with OTOF-related deafness, a disease-modifying therapy is not an abstraction. For regulators, a 61-day review is not a miracle. It is a process that now has to explain itself.

That explanation need not discredit the approval. It can strengthen it. If the pilot can show how unmet need, evidence quality, manufacturing review, and post-approval durability obligations were balanced, Otarmeni becomes the program's proof of concept rather than its easy target.

The clock was the headline last week. The criteria are the headline now.

-- KENJI NAKAMURA, Tokyo